tiprankstipranks
TipRanksStock Market NewsIMTX NewsAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Mesoblast (MESO) and Immatics (IMTX)
Blurbs

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Mesoblast (MESO) and Immatics (IMTX)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Mesoblast (MESOResearch Report) and Immatics (IMTXResearch Report).

Mesoblast (MESO)

Chardan Capital analyst Keay Nakae maintained a Sell rating on Mesoblast today and set a price target of $2.50. The company’s shares closed last Thursday at $3.41, close to its 52-week low of $3.23.

According to TipRanks.com, Nakae is a 4-star analyst with an average return of 6.8% and a 39.4% success rate. Nakae covers the Healthcare sector, focusing on stocks such as Sonnet BioTherapeutics Holdings, Better Therapeutics, Inc., and Arrowhead Pharmaceuticals.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Mesoblast with a $9.25 average price target.

See the top stocks recommended by analysts >>

Immatics (IMTX)

Jefferies analyst Kelly Shi maintained a Buy rating on Immatics yesterday and set a price target of $20.00. The company’s shares closed last Thursday at $7.79.

According to TipRanks.com, Shi is ranked 0 out of 5 stars with an average return of -40.8% and a 11.4% success rate. Shi covers the Healthcare sector, focusing on stocks such as C4 Therapeutics, Legend Biotech, and Adicet Bio.

Currently, the analyst consensus on Immatics is a Strong Buy with an average price target of $20.00.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on MESO:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More